OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

NCT ID: NCT01755286

Last Updated: 2013-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to describe the safety and tolerability of two dose levels of OTO-201, placebo and sham when administered intra-operatively in pediatric subjects with bilateral middle ear effusion who require tympanostomy tube placement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4 mg OTO-201

Group Type EXPERIMENTAL

OTO-201

Intervention Type DRUG

Single intra-operative injection

12 mg OTO-201

Group Type EXPERIMENTAL

OTO-201

Intervention Type DRUG

Single intra-operative injection

Vehicle for OTO-201

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Single intratympanic injection

Sham

Group Type SHAM_COMPARATOR

Sham

Intervention Type DRUG

Simulated single intratympanic injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OTO-201

Single intra-operative injection

Intervention Type DRUG

Placebo

Single intratympanic injection

Intervention Type DRUG

Sham

Simulated single intratympanic injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ciprofloxacin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is a male or female aged 6 months to 12 years, inclusive
* Subject has a clinical diagnosis of bilateral middle ear effusion requiring tympanostomy tube placement
* Subject's caregiver is willing to comply with the protocol and attend all study visits

Exclusion Criteria

* Subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with tympanostomy tube placement
* Subject has a history of sensorineural hearing loss
* Subject has a history of chronic or recurrent bacterial infections other than otitis media that likely will require treatment with antibiotics during the course of the study
Minimum Eligible Age

6 Months

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otonomy, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carl LeBel, PhD

Role: STUDY_CHAIR

Otonomy, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Call/Email Otonomy Central Contact for Trial Locations

San Diego, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201-201101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vaccination for Middle Ear Infection
NCT00001605 COMPLETED PHASE1
Posterior Vs. Anterior Tympanostomy Tube Placement
NCT06191562 ACTIVE_NOT_RECRUITING NA
OTO-313 in Subjects With Subjective Tinnitus
NCT03918109 COMPLETED PHASE1/PHASE2
OTO-104 for Meniere's Disease
NCT01084525 COMPLETED PHASE1